Nido Biosciences announced it will wind down operations in early 2026 after Phase II data fell short of expectations, the company said in a LinkedIn post. The Boston‑area biotech, which had been testing a lead candidate in oncology, indicated it cannot continue development with current results and capital resources. The closure underscores persistent de‑risking challenges for small biotechs moving from early clinical proof‑of‑concept to larger, definitive studies. Venture and public investors will scrutinize whether any assets or IP are available for acquisition or licensing as part of the wind‑down process.